Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation
Authors
Xie, WRegan, MM
Buyse, M
Halabi, S
Kantoff, PW
Sartor, O
Soule, H
Berry, D
Clarke, Noel W
Collette, L
D'Amico, A
Lourenco, RA
Dignam, J
Eisenberger, M
James, N
Fizazi, K
Gillessen, S
Loriot, Y
Mottet, N
Parulekar, W
Sandler, H
Spratt, DE
Sydes, MR
Tombal, B
Williams, S
Sweeney, CJ
Affiliation
Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.Issue Date
2020
Metadata
Show full item recordAbstract
Purpose: Recently, we have shown that metastasis-free survival is a strong surrogate for overall survival (OS) in men with intermediate- and high-risk localized prostate cancer and can accelerate the evaluation of new (neo)adjuvant therapies. Event-free survival (EFS), an earlier prostate-specific antigen (PSA)-based composite end point, may further expedite trial completion. Methods: EFS was defined as the time from random assignment to the date of first evidence of disease recurrence, including biochemical failure, local or regional recurrence, distant metastasis, or death from any cause, or was censored at the date of last PSA assessment. Individual patient data from trials within the Intermediate Clinical Endpoints in Cancer of the Prostate-ICECaP-database with evaluable PSA and disease follow-up data were analyzed. We evaluated the surrogacy of EFS for OS using a 2-stage meta-analytic validation model by determining the correlation of EFS with OS (patient level) and the correlation of treatment effects (hazard ratios [HRs]) on both EFS and OS (trial level). A clinically relevant surrogacy was defined a priori as an R2 ? 0.7. Results: Data for 10,350 patients were analyzed from 15 radiation therapy-based trials enrolled from 1987 to 2011 with a median follow-up of 10 years. At the patient level, the correlation of EFS with OS was 0.43 (95% CI, 0.42 to 0.44) as measured by Kendall's tau from a copula model. At the trial level, the R2 was 0.35 (95% CI, 0.01 to 0.60) from the weighted linear regression of log(HR)-OS on log(HR)-EFS. Conclusion: EFS is a weak surrogate for OS and is not suitable for use as an intermediate clinical end point to substitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therapies for primary radiation therapy-based trials.Citation
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020:JCO1903114.Journal
Journal of Clinical OncologyDOI
10.1200/jco.19.03114PubMed ID
32552276Additional Links
https://dx.doi.org/10.1200/jco.19.03114Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/jco.19.03114
Scopus Count
Collections
Related articles
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
- Authors: Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ, ICECaP Working Group
- Issue date: 2017 Sep 20
- Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
- Authors: Xie W, Ravi P, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Dignam J, James N, Fizazi K, Gillessen S, Mottet N, Murphy L, Parulekar W, Sandler H, Tombal B, Williams S, Sweeney CJ
- Issue date: 2024 Mar
- Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.
- Authors: Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, Shipley WU, Seiferheld W, Lukka HR, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Hall WA, Dess RT, Lovett RD, Balogh AG, Feng FY, Spratt DE
- Issue date: 2022 Sep 20
- Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
- Authors: Feng F, Miladinovic B, Zhang K, Dignam JJ, Wang D, Yu M, Sandler H
- Issue date: 2023 Sep
- Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
- Authors: Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH, European Organisation for Research and Treatment of Cancer, Limburgs Universitair Centrum, AstraZeneca Pharmaceuticals
- Issue date: 2005 Sep 1